Register entry
MUNDIPHARMA GMBH
- Registered sites
- 0
- Active NDC listings
- 0
- Live patents
- 7
- Exclusivities
- 1
- Countries
- 0
Exclusivity
Patents and exclusivities
7| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 11654196 | REZZAYOrezafungin acetate | substance, product | Mar 2032 |
| 10702573 | REZZAYOrezafungin acetate | substance, product | Mar 2033 |
| 9526835 | REZZAYOrezafungin acetate | substance, product | Mar 2033 |
| 8722619 | REZZAYOrezafungin acetate | substance, product | May 2036 |
| 11712459 | REZZAYOrezafungin acetate | product | Mar 2037 |
| 11819533 | REZZAYOrezafungin acetate | substance, product | Jul 2038 |
| 11197909 | REZZAYOrezafungin acetate | substance, product | Jul 2038 |
| Product | Exclusivity | Until |
|---|---|---|
| REZZAYOREZAFUNGIN ACETATE | GAIN Qualified infectious disease product (GAIN) | Mar 2035 |
Enquiry
Common questions
- Is MUNDIPHARMA GMBH FDA approved?
- MUNDIPHARMA GMBH holds no registered establishment of its own; it appears here on its Orange Book patents.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.